Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation

Carolina Simioni, Alice Cani, Alberto M. Martelli, Giorgio Zauli, Giovanna Tabellini, James McCubrey, Silvano Capitani, Luca M. Neri

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The PI3K/Akt/mTOR signaling cascade is a key regulatory pathway controlling cell growth and survival, and its dysregulation is a reported feature of B-precursor acute lymphoblastic leukemia (B-pre ALL). Torin-2 is a novel, second-generation ATP-competitive inhibitor that is potent and selective for mTOR with a superior pharmacokinetic profile to previous inhibitors. It has been shown that Torin-2 displayed dramatic antiproliferative activity across a panel of cancer cell lines. To investigate if Torin-2 could represent a new option for the treatment of B-pre ALL, we tested its activity on a panel of B-pre ALL cell lines. In all of them Torin-2 showed a powerful cytotoxic activity, inhibiting the growth of each cell line in a dose-dependent manner, with an IC50 in the nanomolar range. Torin-2 caused both apoptosis and autophagy, induced cell cycle arrest in G0/G1 phase and affected both mTORC1 and mTORC2 activities as assessed by their specific substrate dephosphorylation. Torin-2 alone suppressed feedback activation of PI3K/Akt, whereas the mTORC1 inhibitor RAD001 required the addition of the Akt inhibitor MK-2206 to achieve the same effect. These pharmacological strategies targeting PI3K/Akt/mTOR at different points of the signaling pathway cascade might represent a new promising therapeutic strategy for treatment of B-pre ALL patients.

Original languageEnglish
Pages (from-to)10034-10047
Number of pages14
JournalOncotarget
Volume5
Issue number20
Publication statusPublished - 2014

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phosphatidylinositol 3-Kinases
Cell Line
Therapeutics
Cell Cycle Resting Phase
Autophagy
G1 Phase
Growth
Cell Cycle Checkpoints
Inhibitory Concentration 50
torin
Cell Survival
Pharmacokinetics
Adenosine Triphosphate
Pharmacology
Apoptosis
Neoplasms

Keywords

  • Akt
  • B-pre acute lymphoblastic leukemia
  • mTOR
  • Targeted therapy
  • Torin-2

ASJC Scopus subject areas

  • Oncology

Cite this

Simioni, C., Cani, A., Martelli, A. M., Zauli, G., Tabellini, G., McCubrey, J., ... Neri, L. M. (2014). Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget, 5(20), 10034-10047.

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. / Simioni, Carolina; Cani, Alice; Martelli, Alberto M.; Zauli, Giorgio; Tabellini, Giovanna; McCubrey, James; Capitani, Silvano; Neri, Luca M.

In: Oncotarget, Vol. 5, No. 20, 2014, p. 10034-10047.

Research output: Contribution to journalArticle

Simioni, C, Cani, A, Martelli, AM, Zauli, G, Tabellini, G, McCubrey, J, Capitani, S & Neri, LM 2014, 'Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation', Oncotarget, vol. 5, no. 20, pp. 10034-10047.
Simioni, Carolina ; Cani, Alice ; Martelli, Alberto M. ; Zauli, Giorgio ; Tabellini, Giovanna ; McCubrey, James ; Capitani, Silvano ; Neri, Luca M. / Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. In: Oncotarget. 2014 ; Vol. 5, No. 20. pp. 10034-10047.
@article{9ac8c2f4b66c4423b3a170cdc09326c7,
title = "Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation",
abstract = "The PI3K/Akt/mTOR signaling cascade is a key regulatory pathway controlling cell growth and survival, and its dysregulation is a reported feature of B-precursor acute lymphoblastic leukemia (B-pre ALL). Torin-2 is a novel, second-generation ATP-competitive inhibitor that is potent and selective for mTOR with a superior pharmacokinetic profile to previous inhibitors. It has been shown that Torin-2 displayed dramatic antiproliferative activity across a panel of cancer cell lines. To investigate if Torin-2 could represent a new option for the treatment of B-pre ALL, we tested its activity on a panel of B-pre ALL cell lines. In all of them Torin-2 showed a powerful cytotoxic activity, inhibiting the growth of each cell line in a dose-dependent manner, with an IC50 in the nanomolar range. Torin-2 caused both apoptosis and autophagy, induced cell cycle arrest in G0/G1 phase and affected both mTORC1 and mTORC2 activities as assessed by their specific substrate dephosphorylation. Torin-2 alone suppressed feedback activation of PI3K/Akt, whereas the mTORC1 inhibitor RAD001 required the addition of the Akt inhibitor MK-2206 to achieve the same effect. These pharmacological strategies targeting PI3K/Akt/mTOR at different points of the signaling pathway cascade might represent a new promising therapeutic strategy for treatment of B-pre ALL patients.",
keywords = "Akt, B-pre acute lymphoblastic leukemia, mTOR, Targeted therapy, Torin-2",
author = "Carolina Simioni and Alice Cani and Martelli, {Alberto M.} and Giorgio Zauli and Giovanna Tabellini and James McCubrey and Silvano Capitani and Neri, {Luca M.}",
year = "2014",
language = "English",
volume = "5",
pages = "10034--10047",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "20",

}

TY - JOUR

T1 - Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation

AU - Simioni, Carolina

AU - Cani, Alice

AU - Martelli, Alberto M.

AU - Zauli, Giorgio

AU - Tabellini, Giovanna

AU - McCubrey, James

AU - Capitani, Silvano

AU - Neri, Luca M.

PY - 2014

Y1 - 2014

N2 - The PI3K/Akt/mTOR signaling cascade is a key regulatory pathway controlling cell growth and survival, and its dysregulation is a reported feature of B-precursor acute lymphoblastic leukemia (B-pre ALL). Torin-2 is a novel, second-generation ATP-competitive inhibitor that is potent and selective for mTOR with a superior pharmacokinetic profile to previous inhibitors. It has been shown that Torin-2 displayed dramatic antiproliferative activity across a panel of cancer cell lines. To investigate if Torin-2 could represent a new option for the treatment of B-pre ALL, we tested its activity on a panel of B-pre ALL cell lines. In all of them Torin-2 showed a powerful cytotoxic activity, inhibiting the growth of each cell line in a dose-dependent manner, with an IC50 in the nanomolar range. Torin-2 caused both apoptosis and autophagy, induced cell cycle arrest in G0/G1 phase and affected both mTORC1 and mTORC2 activities as assessed by their specific substrate dephosphorylation. Torin-2 alone suppressed feedback activation of PI3K/Akt, whereas the mTORC1 inhibitor RAD001 required the addition of the Akt inhibitor MK-2206 to achieve the same effect. These pharmacological strategies targeting PI3K/Akt/mTOR at different points of the signaling pathway cascade might represent a new promising therapeutic strategy for treatment of B-pre ALL patients.

AB - The PI3K/Akt/mTOR signaling cascade is a key regulatory pathway controlling cell growth and survival, and its dysregulation is a reported feature of B-precursor acute lymphoblastic leukemia (B-pre ALL). Torin-2 is a novel, second-generation ATP-competitive inhibitor that is potent and selective for mTOR with a superior pharmacokinetic profile to previous inhibitors. It has been shown that Torin-2 displayed dramatic antiproliferative activity across a panel of cancer cell lines. To investigate if Torin-2 could represent a new option for the treatment of B-pre ALL, we tested its activity on a panel of B-pre ALL cell lines. In all of them Torin-2 showed a powerful cytotoxic activity, inhibiting the growth of each cell line in a dose-dependent manner, with an IC50 in the nanomolar range. Torin-2 caused both apoptosis and autophagy, induced cell cycle arrest in G0/G1 phase and affected both mTORC1 and mTORC2 activities as assessed by their specific substrate dephosphorylation. Torin-2 alone suppressed feedback activation of PI3K/Akt, whereas the mTORC1 inhibitor RAD001 required the addition of the Akt inhibitor MK-2206 to achieve the same effect. These pharmacological strategies targeting PI3K/Akt/mTOR at different points of the signaling pathway cascade might represent a new promising therapeutic strategy for treatment of B-pre ALL patients.

KW - Akt

KW - B-pre acute lymphoblastic leukemia

KW - mTOR

KW - Targeted therapy

KW - Torin-2

UR - http://www.scopus.com/inward/record.url?scp=84927147293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927147293&partnerID=8YFLogxK

M3 - Article

C2 - 25296981

AN - SCOPUS:84927147293

VL - 5

SP - 10034

EP - 10047

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -